GeneDx Holdings Corp. (WGS) Stock Price & Analysis
GeneDx Holdings Corp. (WGS) closed at USD 56.15 on Friday, October 23, 2026, down 16.37% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 56.15; the Oct 23, 2026 session ranged USD 55–67.4 on volume of 2,546,573 shares. Market capitalization is —, with a 52-week range of USD 32.21–170.87 (NMS). Source: Nexqual, retrieved October 24, 2026 at 13:34 UTC.
Also available as compact Markdown for AI agents: nexqual.com/WGS.md
Key facts (WGS)
- Last four reported quarters (through Jun 30, 2026): revenue $454M, net income -$106M (-23.4% margin), free cash flow -$75.8M (SEC filings).
- Insider open-market sales, last ~7 months: 12 Form 4 filings, $3.2M; 12 not under a Rule 10b5-1 plan ($3.2M); 0 by opportunistic insiders, 12 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 4 Form 4 filings, $93.1M; 0 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y -56.4% vs S&P 500 +13.4%; 5Y -78.9% vs S&P 500 +76.9%.
- Next earnings: 2026-11-09, EPS estimate USD 0.07, revenue estimate $123M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (WGS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $212M | $235M | $203M | $305M | $428M | $454M |
| Gross profit | -$16.6M | -$26.8M | $90.0M | $194M | $298M | — |
| Operating income | -$446M | -$668M | -$181M | -$23.2M | -$13.1M | -$92.4M |
| Net income | -$245M | -$549M | -$176M | -$52.3M | -$21.0M | -$106M |
| EPS (diluted) | -$74.91 | -$53.63 | -$7.23 | -$1.94 | -$0.73 | — |
| Free cash flow | -$200M | -$326M | -$185M | -$34.0M | $14.3M | -$75.8M |
| Gross margin | -7.8% | -11.4% | 44.4% | 63.6% | 69.7% | — |
| Operating margin | -210.3% | -284.5% | -89.2% | -7.6% | -3.1% | -20.3% |
| Net margin | -115.6% | -233.9% | -86.8% | -17.1% | -4.9% | -23.4% |
| Revenue growth | +18.3% | +10.6% | -13.7% | +50.8% | +40.0% | — |
| Cash + short-term investments | $401M | $124M | $130M | $141M | $171M | — |
| Total debt | $11.0M | $11.0M | $56.3M | $55.8M | $54.5M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (WGS)
Insider sales (SEC Form 4, open-market, last ~7 months) (WGS)
0 of 12 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-16 | Stueland Katherine | CHIEF EXECUTIVE OFFICER | 10,501 | $1.0M | 8.3% | No | Routine (sold in Mar & Jun & Sep & Dec each year 2023–2025) |
| 2026-09-16 | Feeley Kevin | CHIEF FINANCIAL OFFICER | 3,728 | $364K | 7.7% | No | Routine (sold in Mar & Jun & Sep & Dec each year 2023–2025) |
| 2026-09-09 | Stueland Katherine | CHIEF EXECUTIVE OFFICER | 3,692 | $311K | 3.3% | No | Routine (sold in Mar & Jun & Sep & Dec each year 2023–2025) |
| 2026-09-09 | Feeley Kevin | CHIEF FINANCIAL OFFICER | 1,285 | $108K | 3% | No | Routine (sold in Mar & Jun & Sep & Dec each year 2023–2025) |
| 2026-09-01 | Feeley Kevin | CHIEF FINANCIAL OFFICER | 372 | $31K | 0.9% | No | Routine (sold in Mar & Jun & Sep & Dec each year 2023–2025) |
| 2026-06-16 | Feeley Kevin | CHIEF FINANCIAL OFFICER | 3,729 | $227K | 8.5% | No | Routine (sold in Mar & Jun & Sep & Dec each year 2023–2025) |
| 2026-06-16 | Stueland Katherine | CHIEF EXECUTIVE OFFICER | 10,501 | $638K | 9.1% | No | Routine (sold in Mar & Jun & Sep & Dec each year 2023–2025) |
| 2026-06-09 | Feeley Kevin | CHIEF FINANCIAL OFFICER | 1,266 | $68K | 3.4% | No | Routine (sold in Mar & Jun & Sep & Dec each year 2023–2025) |
| 2026-06-09 | Stueland Katherine | CHIEF EXECUTIVE OFFICER | 3,639 | $196K | 3.6% | No | Routine (sold in Mar & Jun & Sep & Dec each year 2023–2025) |
| 2026-06-01 | Feeley Kevin | CHIEF FINANCIAL OFFICER | 369 | $19K | 1% | No | Routine (sold in Mar & Jun & Sep & Dec each year 2023–2025) |
| 2026-04-29 | Stueland Katherine | CHIEF EXECUTIVE OFFICER | 2,172 | $142K | 2.3% | No | Routine (sold in Mar & Jun & Sep & Dec each year 2023–2025; this trade is outside those months) |
| 2026-04-29 | Feeley Kevin | CHIEF FINANCIAL OFFICER | 392 | $26K | 1.1% | No | Routine (sold in Mar & Jun & Sep & Dec each year 2023–2025; this trade is outside those months) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (WGS)
4 purchases, $93.1M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-06-04…2026-06-05 | Casdin Capital, Llc | Director | 200,000 | $11.1M | 55.55 | Too little history (no open-market trades in 2023) |
| 2026-05-18…2026-05-20 | Casdin Capital, Llc | Director | 500,000 | $21.5M | 42.92 | Too little history (no open-market trades in 2023) |
| 2026-05-13…2026-05-15 | Meister Keith A. | Director | 351,273 | $13.8M | 39.19 | Too little history (no open-market trades in 2024) |
| 2026-05-07…2026-05-11 | Meister Keith A. | Director | 1,205,147 | $46.8M | 38.84 | Too little history (no open-market trades in 2024) |
Analysts (WGS)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-01 | Guggenheim | Target raised | Buy | $74 → $83 |
| 2026-08-04 | Canaccord Genuity | Target raised | Buy | $75 → $90 |
| 2026-08-04 | BTIG | Reiterated | Buy | $90 |
| 2026-06-29 | Guggenheim | Target raised | Buy | $70 → $74 |
Total return (dividends reinvested) (WGS)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -56.4% | -78.9% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -56.5% | -26.8% |
| Volatility (annualized) | 99.3% | 113.9% |
| Max drawdown | -79.4% (Nov 2025→May 2026) | -99.5% (Nov 2021→Nov 2023) |
WGS revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Diagnostic Test | $111.9M | 97.8% | +11.8% |
| — Patients with third-party insurance (part of Diagnostic Test) | $94.7M | 82.8% | +16.8% |
| — Institutional customers (part of Diagnostic Test) | $16.1M | 14.1% | -13.6% |
| — Self-pay patients (part of Diagnostic Test) | $1.0M | 0.9% | +207.4% |
| Other revenue | $2.6M | 2.2% | -1.5% |
| Total revenue | $114.4M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
WGS suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | ILLUMINA, INC. (ILMN) | “In addition, there are a large number of new entrants into the market for genetic information ranging from informatics and analysis pipeline developers to focused, integrated providers of genetic tools and services for health and wellness, including Illumina, Inc., which is also one of our suppliers.” |
| Supplier | Life Technologies | “We rely on a limited number of suppliers, including Illumina, Inc., Life Technologies Corporation, Twist Biosciences Corporation, Path-Tec LLC and Agilent Technologies. for certain laboratory reagents, as well as sequencers and other equipment and materials, which we use in our laboratory operations.” |
| Supplier | Twist Biosciences | “We rely on a limited number of suppliers, including Illumina, Inc., Life Technologies Corporation, Twist Biosciences Corporation, Path-Tec LLC and Agilent Technologies. for certain laboratory reagents, as well as sequencers and other equipment and materials, which we use in our laboratory operations.” |
| Supplier | Path-Tec | “We rely on a limited number of suppliers, including Illumina, Inc., Life Technologies Corporation, Twist Biosciences Corporation, Path-Tec LLC and Agilent Technologies. for certain laboratory reagents, as well as sequencers and other equipment and materials, which we use in our laboratory operations.” |
| Partner | Fabric Genomics | “In tandem with these testing markets, we see potential upside as we put a growth strategy behind our data and biopharma partnerships business, expand internationally with Fabric Genomics, and unlock precision medicine opportunities.” |
| Partner | Casdin Partners Master Fund | “Entities affiliated with Casdin Partners Master Fund, L.P. ("Casdin Partners"), and Corvex Management, L.P. ("Corvex Management") are some of our significant stockholders, which owned approximately 11%, and 12%, respectively, of our outstanding shares of our Class A common stock as of December 31, 2025.” |
| Partner | Corvex Management | “Entities affiliated with Casdin Partners Master Fund, L.P. ("Casdin Partners"), and Corvex Management, L.P. ("Corvex Management") are some of our significant stockholders, which owned approximately 11%, and 12%, respectively, of our outstanding shares of our Class A common stock as of December 31, 2025.” |
Quoted from the company's 10-K filed Feb 23, 2026.
WGS customer concentration
In the period ended Jun 30, 2026, 2 direct customers each accounted for at least 10% (31%, 25%) of revenue, per the company's 10-Q filed Aug 3, 2026. The company does not name them.
WGS company outlook (results filed Aug 3, 2026)
- “GeneDx has reaffirmed its full year 2026 guidance and has provided guidance for the third quarter of 2026.”
Quoted word-for-word from the SEC 8-K results press release.
WGS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.07 | $0.10 | -28.9% | $122.9M | 7 |
| Next quarter (ends Dec 2026) | $0.32 | $0.32 | +0.0% | $142.6M | 7 |
| Current fiscal year (ends Dec 2026) | $0.13 | $-0.06 | -306.2% | $481.8M | 7 |
| Next fiscal year (ends Dec 2027) | $1.20 | $1.10 | +8.6% | $599.0M | 7 |
WGS options: expected move
Options price a move of about ±32.3% (±$19.85) by Nov 13, 2026, which includes earnings on Nov 9, 2026. Over the last 8 reports the stock moved ±24% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 6 | 172.9% | ±19.2% |
| Nov 6, 2026 | 13 | 187.9% | ±28.6% |
| Nov 13, 2026 | 20 | 174.9% | ±32.3% |
| Nov 20, 2026 | 27 | 152.8% | ±32.5% |
| Nov 27, 2026 | 34 | 146.0% | ±34.6% |
| Dec 4, 2026 | 41 | 135.1% | ±35.1% |
| Dec 18, 2026 | 55 | 125.7% | ±38.3% |
| Jan 15, 2027 | 83 | 108.9% | ±40.4% |
30-day implied volatility 151.2% vs 93.1% realized over the last 30 trading days. Put/call ratio (volume) 8.32. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 24, 2026 at 13:34 UTC)
| Price | USD 56.15 |
|---|---|
| Change | ▼ 16.37% (down) |
| Previous Close | USD 56.15 |
| Open | USD 56.15 |
| Day Range | USD 55 – 67.4 |
| 52-Week Range | USD 32.21 – 170.87 |
| Volume | 2,546,573 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (WGS)
Nexqual's technical model rates WGS "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 13:34 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 32.65 (neutral) |
| vs SMA50 | Below (USD 80.35) |
| MACD | -5.01 (negative) |
Earnings (WGS)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD 0.07 |
| Revenue Estimate | $122.93M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.01 vs est -0.19 ▲ beat |
| 2026-03-31 | USD -0.28 vs est -0.02 ▼ miss |
| 2025-12-31 | USD 0.14 vs est 0.12 ▲ beat |
| 2025-09-30 | USD 0.49 vs est 0.42 ▲ beat |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
Financials & Fundamentals (WGS)
| Total Revenue | $454.43M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +11.40% |
| Gross Margin | +69.38% |
| Operating Margin | -15.21% |
| Profit Margin | -23.41% |
| ROE | -40.80% |
| Debt / Equity | 0.69 |
| Current Ratio | 3.3 |
| Total Cash | $132.55M |
| Total Debt | $167.40M |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
Ownership (WGS)
| Insider Ownership | +7.71% |
|---|---|
| Institutional Ownership | +108.64% |
| Shares Outstanding | 29.82M |
| Float | 20.44M |
| Short % of Float | +36.11% |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
From GeneDx Holdings Corp.'s Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- GeneDx combines clinical expertise, advanced technology, and the proprietary GeneDx Infinity™ dataset to power the ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device Designation – enabling clinicians to deliver precise, fast, and actionable diagnoses.
- To achieve these objectives, we: •Deploy our team of approximately 120 field-based sales representatives and medical science liaisons, and construct an industry-leading brand, product, marketing, communications and market access platform that leverages our expertise, rich data, and decades of earned trust across the genetics community. •Partner with leaders across health systems, manufacturers, commercial and governmental payors and advocacy groups.
- Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, these steps may be circumvented, or third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.
- We are also applying AI tools – like our machine learning powered gene ranker, Multiscore – on top of GeneDx InfinityTM to harness the power of our data, scale our platform and increase speed and turnaround time.
Legal & Regulatory Risks (Item 1A, quoted)
- We may be subject to increased compliance risks as a result of our rapid growth, including our dependence on our sales, marketing and billing efforts.
- Changes in FDA oversight for laboratory developed tests LDTs could subject our operations to much more significant regulatory requirements.
- Compliance with the HIPAA security, privacy and breach notification regulations may increase our costs.
- We are also required to comply with applicable state privacy, security and breach notification laws and regulations, which may be more stringent than federal HIPAA requirements.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PSNL | Personalis, Inc. | USD 15.85 | ▲ 0.19% |
| NEO | NeoGenomics, Inc. | USD 16.59 | ▲ 1.22% |
| FRNM | Freenome, Inc. | USD 12.77 | ▼ 2.52% |
| OPK | Opko Health, Inc. | USD 1.63 | ▲ 0% |
| CSTL | Castle Biosciences, Inc. | USD 33.08 | ▼ 0.33% |
| CDNA | CareDx, Inc. | USD 69.21 | ▲ 0.07% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 13:34 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt